1. What This Condition Is
Leukemia is a cancer of the blood and bone marrow characterized by the uncontrolled proliferation of abnormal white blood cells. There are multiple types of leukemia, classified by the rate of progression (acute versus chronic) and the cell type affected (lymphocytic versus myelogenous). Veterans most commonly encounter three forms relevant to VA service connection: Chronic Lymphocytic Leukemia (CLL), the most prevalent adult leukemia; Hairy Cell Leukemia (HCL); and other chronic B-cell leukemias. Symptoms vary by type and stage but generally include fatigue, enlarged lymph nodes, frequent infections, easy bruising or bleeding, and weight loss.
Leukemia qualifies for VA presumptive service connection through two separate regulatory pathways covering different veteran populations.
Agent Orange presumptive (38 CFR 3.309(e)): The chronic B-cell leukemias — CLL, hairy cell leukemia, and other B-lymphocyte malignancies — are among the original Agent Orange presumptive conditions. Vietnam-era veterans exposed to tactical herbicides during qualifying service do not need to prove a direct medical nexus. The presumptive covers veterans who served in Vietnam, the Korean Demilitarized Zone between April 1, 1968 and August 31, 1971, Air Force veterans who handled or maintained herbicide-sprayed aircraft, veterans at specific stateside testing locations, and Blue Water Navy veterans under the 2019 act.
Gulf War and post-9/11 presumptive (38 CFR 3.320b, effective January 10, 2025): A new regulation effective January 10, 2025 establishes presumptive service connection for acute leukemias, chronic leukemias, multiple myelomas, myelodysplastic syndromes, and myelofibrosis for covered veterans who served on or after August 2, 1990 in the Southwest Asia theater of operations or Somalia, or who served in qualifying post-9/11 locations. Veterans covered under 38 CFR 3.320b — including veterans with acute leukemias not previously covered under the Agent Orange presumptive — now have a separate presumptive pathway based on exposure to fine particulate matter and airborne hazards during qualifying service. This is a significant expansion from the prior Agent Orange-only pathway.
Veterans with any leukemia diagnosis and qualifying military service should file and allow the VA to make the determination rather than self-screening out. Both pathways should be argued in the alternative where the veteran's service history supports them.
2. VA Rating Criteria
Leukemia is rated under 38 CFR § 4.117, Diagnostic Code 7703 (Leukemia).
Active disease or treatment: A 100% rating applies during any period of active leukemia or during any treatment — including chemotherapy, targeted therapy (ibrutinib, venetoclax), immunotherapy, bone marrow or stem cell transplantation, or any other systemic therapy.
Chronic phase leukemia under active monitoring: Some veterans with CLL are in "watch and wait" — under observation without active treatment. During watch-and-wait phases, the rating is based on current symptoms and functional impairment rather than the 100% active treatment rating.
Post-treatment or remission: Following completion of a defined treatment course or after stem cell transplantation, the 100% rating continues for a minimum of six months. After that period, the VA schedules a rating examination to assess residual disability.
Residual ratings: Common residuals after leukemia treatment include:
- Peripheral neuropathy from chemotherapy agents
- Bone marrow failure with anemia or thrombocytopenia
- Immunosuppression and recurrent serious infections
- Graft-versus-host disease (GVHD) after stem cell transplant
- Secondary organ damage from chemotherapy toxicity
Each residual is evaluated separately under the applicable diagnostic code. GVHD produces multi-system effects and may generate separate ratings for skin, gastrointestinal, ocular, and pulmonary manifestations.
For veterans in watch-and-wait with CLL who are not actively treated but who have cytopenias (low blood counts), lymphadenopathy (enlarged lymph nodes), or systemic symptoms (fatigue, night sweats, weight loss), the rating is based on those functional findings.
3. What to Expect at Your C&P Exam
For active disease or treatment, the examiner confirms diagnosis, treatment status, and functional limitations. Bring current hematology records including complete blood count, peripheral blood smear findings, bone marrow biopsy, flow cytometry, and imaging showing lymphadenopathy or splenomegaly.
For a watch-and-wait CLL claim, describe your current symptoms: fatigue and its impact on daily activity, night sweats, lymph node swelling, and any infections that required hospitalization or prolonged antibiotic treatment. The examiner must document current functional status, not simply the absence of active therapy.
For a residual exam after treatment, describe all persisting residuals: neuropathy, fatigue, anemia symptoms, GVHD manifestations, and any secondary organ involvement. Come prepared with current laboratory data and specialist records.
4. Evidence You Need to Win
Diagnosis: Hematology records confirming the leukemia diagnosis, including peripheral blood studies, bone marrow biopsy, immunophenotyping (flow cytometry), and cytogenetics. Documentation of the specific leukemia type (CLL, hairy cell, etc.) is essential for matching the diagnosis to the Agent Orange presumptive.
Service Record Evidence (Presumptive Claims): Documentation of qualifying service in Vietnam, the Korean DMZ, or other herbicide-exposure locations. For most Vietnam veterans, DD-214 with in-country service dates suffices. For Blue Water Navy veterans, ship logs confirming vessel assignment to territorial seas off Vietnam.
No Nexus Letter Required for Presumptive Claims: The Agent Orange presumptive substitutes for medical nexus. File with the diagnosis and qualifying service documented.
Nexus Letter (Non-Presumptive Direct Claims): For veterans with non-CLL leukemia or whose service does not fall under the Agent Orange presumptive, a hematologist or oncologist's nexus opinion is required.
DBQ Form: The appropriate hematologic malignancy or leukemia DBQ. Your treating hematologist should complete this form with current diagnosis, treatment status, blood count data, and residual functional findings.
Current Laboratory Data: CBC with differential, immunophenotyping results, and any staging information (Rai or Binet staging for CLL).
Residual Documentation: Neuropathy evaluations, organ function labs, GVHD assessment records, and documentation of any treatment complications.
Personal Statement: Describe the functional impact of active disease, treatment, and any watch-and-wait symptoms. For veterans in active monitoring, describe fatigue, night sweats, lymph node swelling, and infection frequency.
Buddy Statements (VA Form 21-10210): Family members or caregivers who can describe the functional burden of the disease and treatment provide lay corroboration.
5. Secondary Conditions to Consider
Peripheral Neuropathy: Chemotherapy agents used for leukemia — particularly vincristine and platinum compounds — cause peripheral neuropathy. Secondary neuropathy from treatment of service-connected leukemia is ratable.
Anemia: Bone marrow suppression from leukemia and its treatment causes chronic anemia requiring transfusions or ESA therapy. Secondary anemia is separately evaluable.
GVHD (Post-Stem Cell Transplant): Graft-versus-host disease can affect the skin, gastrointestinal tract, liver, lungs, and eyes. Each organ system affected may be separately rated under the applicable diagnostic code.
Depression and Anxiety: A leukemia diagnosis, particularly a chronic condition managed with ongoing monitoring and periodic treatment, produces significant psychological burden. Secondary mental health claims are ratable under 38 CFR 3.310.
Secondary Malignancies: Prior chemotherapy with alkylating agents or radiation increases the risk of secondary cancers, including therapy-related myeloid neoplasms. Secondary malignancies from treatment of service-connected leukemia may be ratable.
Immune Compromise and Recurrent Infections: Long-term immunosuppression from CLL or its treatment causes recurrent serious infections that may require hospitalization and produce lasting organ effects.
6. Common Mistakes That Kill Claims
Not filing because the veteran is in watch-and-wait. Watch-and-wait is an active medical status in which the patient is monitored and treated when thresholds are met. It is not "no disease." Veterans with CLL on watch-and-wait have a ratable condition and should file. Symptoms during the monitoring phase are ratable, and the underlying diagnosis supports presumptive service connection regardless of whether treatment has started.
Not knowing CLL is covered by the Agent Orange presumptive. Many CLL patients in the veteran community — and some VSOs — are not aware that chronic B-cell leukemias are listed under 38 CFR 3.309(e). File without delay if you have qualifying service and a CLL diagnosis.
Missing residual claims after transplant. Stem cell transplant is a high-intensity procedure with significant residual effects. Veterans who complete transplant and are then rated at 0% residual have usually failed to document GVHD, neuropathy, fatigue, organ damage, or other measurable residuals. Gather specialist records for each organ system affected.
Not pursuing Blue Water Navy coverage. Veterans who served offshore and were previously denied may now qualify under the Blue Water Navy Vietnam Veterans Act of 2019. File a Supplemental Claim.
Assuming non-CLL leukemia is not service-connectable. While the Agent Orange presumptive is specific to chronic B-cell leukemias, acute leukemias and other forms may be service-connectable through radiation exposure, chemical exposure, or PACT Act coverage depending on the veteran's service history. File and let the VA evaluate.
7. FWD Assist Resources
The following FWD Assist HQ books are directly relevant to a leukemia claim:
- Agent Orange: The Complete Vietnam Veterans Claims Guide — comprehensive coverage of the presumptive list including chronic B-cell leukemias, qualifying service locations, Blue Water Navy provisions, and how to file
- C&P Exam Prep Guide — covers what to expect at a cancer residual exam and how to document hematologic residuals and treatment complications for the rating evaluation
- Secondary Conditions Guide — covers GVHD, chemotherapy neuropathy, anemia, and mental health secondary chains from service-connected leukemia
- The PACT Act Playbook — relevant for veterans whose leukemia claim intersects with post-9/11 service and PACT Act coverage
All titles are available at fwdassisthq.com.
8. Get Help Without a Claim Shark
Free, accredited help is available through Veterans Service Organizations including the DAV, VFW, American Legion, and AMVETS. County Veterans Service Officers (CVSOs) file and manage claims at no cost.
Charging upfront fees to assist with a VA claim is illegal under 38 U.S.C. § 5905. VA-accredited attorneys and claims agents may charge fees only after an initial VA decision, capped at 20% of past-due benefits under 38 U.S.C. § 5904. No legitimate representative asks for money before your first decision.
Verify accreditation at va.gov/ogc/accreditation.asp.